International Translational and Regenerative Medicine Conference


International Translational and Regenerative Medicine Conference (ITMC-2018) conference includes - Areas of research that aims to improve human health and longevity by determining the relevance to human diseases through novel and scientific discoveries available for practical application, especially in relation to biological sciences, life sciences, medicine and engineering.

ITMC-2018- It aims to discover advances in health practice, management and education in relation to health disparities as well as a breadth of other topics - Need for translational medicine, Challenges in translational medicine, Opportunities in translational medicine.

ITMC-2018 conference includes Plenary lectures, Keynote lectures and short courses by eminent personalities from around the world in addition to contributed papers both oral and poster presentations.
Conference mainly focuses on:

• Translational medicine approaches in drug discovery & development
• Cardio-Vascular Translational Medicine
• Translational Haematology
• Translational therapeutics/ Novel therapeutic technologies
• Clinical and Translational Oncology
• Translational Neuroscience
• Pharmacology (Cancer / Clinical)
• Medicinal genetics
• Biomedical sciences / Bioengineering
• Tissue Repair and Regeneration
• Bio Molecular/ Nuclear imaging
• Stem cells/ Regenerative medicine
• Cancer research and regenerative medicine
• Cell & Gene therapy
• Translational Stem Cell Research
• Scaffold in regenerative medicine
• Advances in stem cells and regenerative medicine
• Nanofibers/ Nanomedicine in regenerative medicine

Please mail us at: itmc@madridge.com
Submit your abstracts at: http://itmc.madridge.com/abstract-submission.php

Visitors

Scientists
Translational Research Associates
Clinical Researchers
Professors
Faculty members
Clinicians
Students

Exhibitors

MADRIDGE CONFERENCES

Go to event website

EIN News provides powerful, real-time media monitoring, news aggregation & syndication services. Read the latest news about this topic. See: